EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation

Konstantinos Mengrelis, Mario Wiletel, Romy Steiner iD, Anna M Weijler iD, Laurenz Wolner iD, Valentina Stolz iD, Milos Nikolic, Daniel Simon, Florian Frommlet iD, Jonathan Sprent iD, Hannes Stockinger iD, Nina Pilat iD

Cells · 2025

DOI: 10.3390/cells14141086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Konstantinos Mengrelis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Interleukin-2, Skin Transplantation, Graft Rejection, Immunoglobulin G. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, FWF Austrian Science Fund, Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-mediated rejection (ABMR) caused by donor-specific Abs (DSAs) is still the leading cause of late graft loss following clinical organ transplantation, and effective strategies to combat ABMR are still elusive. We previously showed that rIL-2 complexed with anti-IL-2 mAb clone JES6-1A12 (IL-2 cplx) leads to the selective expansion of regulatory T cells (Tregs) and the prolonged survival of MHC-mismatched skin allografts. Although the grafts were eventually rejected, mice failed to develop DSAs. Here, we investigated the impact of IL-2 cplx on the humoral response and germinal center (GC) reaction during allograft rejection. IL-2 cplx treatment prevents Bcl-6 upregulation, leading to suppressed development of GC T and B cells. The IL-2 cplx-induced impairment of GC development limits IgG allo-Ab production but allows for IgM synthesis. By employing a hapten–carrier system to investigate affinity maturation, we found that IL-2 cplx induces a distinct shift in specific Ab production favoring low-affinity IgM while simultaneously decreasing IgG responses. These findings illuminate the potential of IL-2 cplx therapy for inducing humoral tolerance, potentially paving the way for refining strategies aimed at preventing and treating ABMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Skin TransplantationGraft RejectionImmunoglobulin GIsoantibodiesImmunity, HumoralAllograftsAnimalsMiceMice, Inbred C57BLMice, Inbred BALB CGerminal CenterT-Lymphocytes, RegulatoryTransplantation, Homologous

Stichwörter der Autor:innen

donor-specific antibodiesgerminal centerhumoral toleranceregulatory T cellstransplantation

Substanzen

Interleukin-2Immunoglobulin GIsoantibodies

Autor:innen und Institutionen

  • Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria.
  • Department of General Surgery, Division of Transplantation, Medical University of Vienna, 1090 Vienna, Austria.
  • Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090 Vienna, Austria.
  • Division of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
  • Center for Medical Statistics, Informatics and Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, 1090 Vienna, Austria.
  • Garvan Institute of Medical Research, Immunology Division, Sydney, NSW 2010, Australia.

ORCID-Profile: Romy Steiner, Anna M Weijler, Laurenz Wolner, Valentina Stolz, Florian Frommlet, Jonathan Sprent, Hannes Stockinger, Nina Pilat

Förderung

  • NIAID NIH HHS
  • FWF Austrian Science Fund
  • Austrian Science Fund

Zitieren

APA

Mengrelis, K., Wiletel, M., Steiner, R., Weijler, A. M., Wolner, L., Stolz, V., Nikolic, M., Simon, D., Frommlet, F., Sprent, J., Stockinger, H., & Pilat, N. (2025). IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. Cells. https://doi.org/10.3390/cells14141086

Vancouver

Mengrelis K, Wiletel M, Steiner R, Weijler AM, Wolner L, Stolz V, et al. IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. Cells. 2025. doi:10.3390/cells14141086

BibTeX
@article{Mengrelis2025,
  author = {Mengrelis, Konstantinos and Wiletel, Mario and Steiner, Romy and Weijler, Anna M and Wolner, Laurenz and Stolz, Valentina and Nikolic, Milos and Simon, Daniel and Frommlet, Florian and Sprent, Jonathan and Stockinger, Hannes and Pilat, Nina},
  title = {IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14141086}
}
Kostenlos starten →